💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors  20171012

By JPN, Pharmaceutical

💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors

http://www.ono.co.jp/eng/news/pdf/sm_cn171012.pdf

More from tokioX :

  1. 💊Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
  2. 💰Results Summary for Fiscal 2017 (Year to August 31, 2017)  20171012
  3. 💰7andi , Announcement of Consolidated Financial Results for the Six Months ended August 31, 2017　20171012
  4. 🎗On the partnership between Gpif and the World Bank Group to promote sustainable investment  20171012
  5. Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea  20170919
  6. ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  7. Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma News Release 20170901